Today, Pfizer Inc. announced that US health regulators approved the first drug to treat a rare, progressive lung disease. The company said that the US Food and Drug Administration (FDA) approved its Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and …